BioNexus Gene Lab Corp Stock Drops 3% on Poor RatingsApr 4, 2026BioNexus Gene Lab Corp shares fell 3.08% to $2.18 amid poor technical and fundamental ratings, while operating in chemical raw materials and genomic screening.BioNexus Gene Lab Corp Stock Drops 3% on Poor RatingsChartMillTopic tracking2026-02-23BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman2026-03-12BioNexus Gene Lab Corp. Appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics to Lead VitaGuard™ MRD Commercialization2026-04-04BioNexus Gene Lab Corp Stock Drops 3% on Poor Ratings2026-04-14BioNexus Gene Lab 10-K: Revenue $7.42M, EPS $(1.61)2026-05-15BioNexus Gene Lab Corp Q1 2026 Earnings: Revenue $22.84K, EPS ($0.23)2026-05-29Turning Malaysia into a Bridge for China’s Biotech Ambitions2026-05-29BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development2026-06-05BioNexus Gene Lab (Nasdaq: BGLC) pushes Malaysia–China biotech co-development model2026-06-05BioNexus Gene Lab Urges Malaysia–China Co-Development of Biotech Platforms After Kuala Lumpur Forum2026-06-27Enterprise Value to EBITDA Forward of BioNexus Gene Lab Corp – NASDAQ:BGLCShow all 15 updates
ChemBrief